Abstract: A mobile device protective case set is suitable for cooperating with a mobile device, the mobile device protective case set includes a main frame and an assembling component, the main frame has an inner circular surface, a back flange and at least one positioning portion, the inner circular surface encloses to define a space, the space is suitable for accommodating the mobile device, the back flange protrudes from the inner circular surface towards the space, the back flange has a device abutting surface, which is suitable for a back side of the mobile device to abut, and the positioning portion is disposed at the device abutting surface; the assembling component has a base portion and at least one clamping portion, the clamping portion is disposed at a partial outer periphery of the base portion, the clamping portion is suitable for combining the positioning portion, and the device abutting surface and the clamping portion are suitable to abut against the back side of the mobile device.

Abstract: The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: A virtual reality acupuncture system contains a virtual reality device comprising: a head-mounted display for viewing a virtual scene model and a mannequin, and a joystick for tracking hand movements for needle insertion determination; an computing host that transmits data with a head-mounted display and constructs an acupoint database, and an acupuncture virtual reality application which is executed to build a virtual reality model, in which the acupuncture virtual reality application constructs a situational scene model for simulating the actual condition of the consultation room; and a virtual 3D spherical acupoint model of the human body, which has a sphere area located at a certain depth below the skin surface, and has a skin distance model, so that the needle can sense the distance depth after touching the skin, which can be used to determine whether the needle position is not outside the sphere area.

Abstract: The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Abstract: The present invention demonstrated a Cre-loxP based cofilin-1 transgenic animal model to address the pathophysiological role of over-expressed cofilin-1 on systemic development.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.

Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Abstract: A method of preparing self-adhesive polyester elastomer composite membrane includes the following steps: mix methyl formate or ethyl acetate with thermoplastic polyester elastomer (TPEE) powder or granules; add a modifier, a photo initiator or a thermal initiator; continue mixing to prepare uniformed mixture; after drying uniformed mixture prepare a polyester elastomer membrane through an injection laminating process and apply pressure sensitive adhesive on one side of the polyester elastomer membrane. Prepared membrane poses good bonding characteristics to textile materials and can be used in production of clothing.

Abstract: A multispecific nanobodies chimeric antigen receptor and T-cell engager includes an HLA-G nanobody chimeric antigen receptor and a bispecific T-cell engager. The HLA-G nanobody chimeric antigen receptor includes an HLA-G nanobodies unit, a transmembrane domain, and a CD3z signaling domain. The bispecific T-cell engager includes a PD-L1 nanobodies unit and a CD3e nanobody.

Abstract: A method of preparing polyester elastomer meltblown nonwoven fabric membrane with porous and high bonding strength includes the following steps of: (a) Adding a reaction solvent to a reaction solvent to thermoplastic polyester elastomer (TPEE) powder or granules to prepare a solvent mixture. (b) Adding a modifier to the solvent mixture, and mixing uniformly to prepare a first mixture, the modifier includes at least one of o-xylylenediamine, m-xylylenediamine, alpha, alpha?-diamino-p-xylene, 2,3,5,6-Tetrachloro-p-xylene-alpha,alpha?-diamine, and 1,3,5,7-Tetraazatricyclodecane. (c) Adding an initiator to the first mixture, and mixing uniformly to prepare a second mixture. (d) Drying the second mixture to form a masterbatch, and (e) preparing the polyester elastomer meltblown nonwoven fabric membrane by passing the masterbatch through a meltblown process.

Abstract: A robust conjugate symmetric optical apparatus is disclosed. The robust conjugate symmetric optical apparatus comprises a first optical cell set and a second optical cell set. The first optical cell set includes a first plurality of cells, each of which includes a first left half cell and a first right half cell, and the respective first right half cell and the corresponding first left half cells form a first symmetric structure therebetween.

Abstract: Disclosed is an arthroscopic cannula to solve the problem of more wounds being created due to the use of a plurality of cannulas in a conventional arthroscopic surgery. The arthroscopic cannula includes a cannula body, a spacer provided inside the cannula body and extending axially along the cannula body to divide an internal space of the cannula body into a first chamber and a second chamber, and a joint connected to one end of the cannula body. The interior of the joint intercommunicates with the first chamber and the second chamber.

Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.

Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Abstract: The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Abstract: A method of preparing thermoplastic polyester elastomer membrane with high binding strength includes the following steps: (a) Adding a reaction solvent to TPEE powder or granules to prepare a solvent mixture. (b) Adding a modifier to the solvent mixture, and mixing uniformly to prepare a first mixture, the modifier including at least one of o-xylylenediamine, m-xylylenediamine, alpha,alpha?-diamino-p-xylene, 2,3,5,6-Tetrachloro-p-xylene-alpha,alpha?-diamine, and 1,3,5,7-Tetraazatricyclodecane. (c) Adding an initiator to the first mixture, and mixing uniformly to prepare a second mixture. (d) Obtaining a finished product by passing the second mixture through an injection laminating process.

Abstract: A method of preparing thermoplastic polyester elastomer membrane with high binding strength includes the following steps: (a) Adding a reaction solvent to TPEE powder or granules to prepare a solvent mixture, (b) Adding a modifier to the solvent mixture, and mixing uniformly to prepare a first mixture, the modifier including at least one of o-xylylenediamine, m-xylylenediamine, alpha,alpha?-diamino-p-xylene, 2,3,5,6-Tetrachloro-p-xylene-alpha,alpha?-diamine, and 1,3,5,7-Tetraazatricyclodecane. (c) Adding an initiator to the first mixture, and mixing uniformly to prepare a second mixture, (d) Obtaining a finished product by passing the second mixture through an injection laminating process.

Abstract: A method of preparing polyester elastomer meltblown nonwoven fabric membrane with porous and high bonding strength includes the following steps of: (a) Adding a reaction solvent to a reaction solvent to thermoplastic polyester elastomer (TPEE) powder or granules to prepare a solvent mixture. (b) Adding a modifier to the solvent mixture, and mixing uniformly to prepare a first mixture, the modifier includes at least one of o-xylylenediamine, m-xylylenediamine, alpha, alpha?-diamino-p-xylene, 2,3,5,6-Tetrachloro-p-xylene-alpha,alpha?-diamine, and 1,3,5,7-Tetraazatricyclodecane. (c) Adding an initiator to the first mixture, and mixing uniformly to prepare a second mixture. (d) Drying the second mixture to form a masterbatch, and (e) preparing the polyester elastomer meltblown nonwoven fabric membrane by passing the masterbatch through a meltblown process.